Skip to main content

Advertisement

SpringerLink
Log in

Cytomegalovirus infection in autologous stem cell transplant recipients in the era of rituximab

  • Original Article
  • Published:
Annals of Hematology Aims and scope Submit manuscript

Abstract

The incidence of cytomegalovirus (CMV) reactivation/disease after autologous stem cell transplant (ASCT) is much lower than that after allogeneic stem cell transplantation. With the recent use of rituximab during cancer chemotherapy or conditioning regimens prior to transplantation, there has been an increasing concern of opportunistic infections including CMV. In the present study, we reviewed the patients undergoing ASCT from December 2007 to December 2013 to identify those developing CMV reactivation/disease. Out of the 978 patients who underwent ASCT at the Karmanos Cancer Institute, 239 patients were tested for symptomatic CMV reactivation based on clinical suspicion. Of the tested patients, 7/239 (2.9 %) were documented to have CMV reactivation within 90 days of ASCT. The median time to develop CMV viremia was 32 days from transplantation. Of the 239 patients tested, CMV viremia was detected in 3 out of 72 patients who received rituximab as compared to 4 out of 167 patients who did not. Three of these seven viremic patients were treated with anti-viral drugs; viremia resolved in all patients at a median of 24 days. Three patients were found to develop other bacterial and/or fungal infections following CMV viremia. Two of the seven patients died during 1-year follow-up, due to primary disease progression or Candida sepsis. None of the patients developed proven tissue-invasive CMV disease. The study did not evaluate the incidence of asymptomatic CMV infection/reactivation. Despite prior publications based on limited data, rituximab does not appear to contribute to an increased frequency of symptomatic CMV reactivation following ASCT.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Fassas AB, Bolanos-Meade J, Buddharaju LN et al (2001) Cytomegalovirus infection and non-neutropenic fever after autologous stem cell transplantation: high rates of reactivation in patients with multiple myeloma and lymphoma. Br J Haematol 112:237–241

    Article  CAS  PubMed  Google Scholar 

  2. Boeckh M, Stevens-Ayers T, Bowden RA (1996) Cytomegalovirus pp 65 antigenemia after autologous marrow and peripheral blood stem cell transplantation. J Infect Dis 174:907–912

    Article  CAS  PubMed  Google Scholar 

  3. Konoplev S, Champlin RE, Giralt S et al (2001) Cytomegalovirus pneumonia in adult autologous blood and marrow transplant recipients. Bone Marrow Transplant 27:877–881

    Article  CAS  PubMed  Google Scholar 

  4. Bilgrami S, Aslanzadeh J, Feingold JM et al (1999) Cytomegalovirus viremia, viruria and disease after autologous peripheral blood stem cell transplantation: no need for surveillance. Bone Marrow Transplant 24:69–73

    Article  CAS  PubMed  Google Scholar 

  5. Holmberg LA, Boeckh M, Hooper H et al (1999) Increased incidence of cytomegalovirus disease after autologous CD34-selected peripheral blood stem cell transplantation. Blood 94:4029–4035

    CAS  PubMed  Google Scholar 

  6. Rossini F, Terruzzi E, Cammarota S et al (2005) Cytomegalovirus infection after autologous stem cell transplantation: incidence and outcome in a group of patients undergoing a surveillance program. Transpl Infect Dis Off J Transplant Soc 7:122–125

    Article  CAS  Google Scholar 

  7. Coiffier B, Lepage E, Briere J et al (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346:235–242

    Article  CAS  PubMed  Google Scholar 

  8. Fenske TS, Hari PN, Carreras J et al (2009) Impact of pre-transplant rituximab on survival after autologous hematopoietic stem cell transplantation for diffuse large B cell lymphoma. Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant 15:1455–1464

    Article  CAS  Google Scholar 

  9. Goldberg SL, Pecora AL, Alter RS et al (2002) Unusual viral infections (progressive multifocal leukoencephalopathy and cytomegalovirus disease) after high-dose chemotherapy with autologous blood stem cell rescue and peritransplantation rituximab. Blood 99:1486–1488

    Article  CAS  PubMed  Google Scholar 

  10. Suzan F, Ammor M, Ribrag V (2001) Fatal reactivation of cytomegalovirus infection after use of rituximab for a post-transplantation lymphoproliferative disorder. N Engl J Med 345:1000

    Article  CAS  PubMed  Google Scholar 

  11. Lee MY, Chiou TJ, Hsiao LT et al (2008) Rituximab therapy increased post-transplant cytomegalovirus complications in non-Hodgkin’s lymphoma patients receiving autologous hematopoietic stem cell transplantation. Ann Hematol 87:285–289

    Article  CAS  PubMed  Google Scholar 

  12. Kelesidis T, Daikos G, Boumpas D, Tsiodras S (2011) Does rituximab increase the incidence of infectious complications? A narrative review. Int J Infect Dis IJID Off Publ Int Soc Infect Dis 15:e2–e16

    CAS  Google Scholar 

  13. Al-Rawi O, Abdel-Rahman F, Al-Najjar R et al (2015) Cytomegalovirus reactivation in adult recipients of autologous stem cell transplantation: a single center experience. Mediterr J Hematol Infect Dis 7:e2015049

    Article  PubMed  PubMed Central  Google Scholar 

  14. Marchesi F, Mengarelli A, Giannotti F et al (2014) High incidence of post-transplant cytomegalovirus reactivations in myeloma patients undergoing autologous stem cell transplantation after treatment with bortezomib-based regimens: a survey from the Rome Transplant Network. Transpl Infect Dis Off J Transplant Soc 16:158–164

    Article  CAS  Google Scholar 

  15. Kim JH, Goulston C, Sanders S et al (2012) Cytomegalovirus reactivation following autologous peripheral blood stem cell transplantation for multiple myeloma in the era of novel chemotherapeutics and tandem transplantation. Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant 18:1753–1758

    Article  Google Scholar 

  16. Marchesi F, Pimpinelli F, Dessanti ML et al (2014) Evaluation of risk of symptomatic cytomegalovirus reactivation in myeloma patients treated with tandem autologous stem cell transplantation and novel agents: a single-institution study. Transpl Infect Dis Off J Transplant Soc 16:1032–1038

    Article  CAS  Google Scholar 

Download references

Author information

Author notes

  1. Tania Jain

    Present address: , 5777 E Mayo Boulevard, Phoenix, AZ, USA

Authors and Affiliations

  1. Department of Internal Medicine, Wayne State University/Detroit Medical Center, Detroit, MI, USA

    Tania Jain, Jisha John, Aditya Kotecha, Tanaz Saliminia, Sanjay Revankar & Pranatharthi Chandrasekar

  2. Barbara Ann Karmanos Cancer Institute, Detroit, MI, USA

    Abhinav Deol, Sanjay Revankar & Pranatharthi Chandrasekar

Authors
  1. Tania Jain
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jisha John
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Aditya Kotecha
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Abhinav Deol
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Tanaz Saliminia
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Sanjay Revankar
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Pranatharthi Chandrasekar
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Tania Jain.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Ethics approval

The study was approved by the Institutional Review Board at Wayne State University and Karmanos Cancer Center, Detroit, MI.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Jain, T., John, J., Kotecha, A. et al. Cytomegalovirus infection in autologous stem cell transplant recipients in the era of rituximab. Ann Hematol 95, 1323–1327 (2016). https://doi.org/10.1007/s00277-016-2700-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-016-2700-4

Keywords

Search

Navigation